China’s Akeso says new cancer drug beats AstraZeneca’s in trial
Kort samengevat
Chinese biopharmaceutical firm Akeso has announced that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase three trial for biliary tract cancer, reports the …
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij China Economic Review.
Lees het volledige bericht ↗